Clinical trials: Abuse, Drug
Drug Abuse
Testing a Multilevel Preventive Intervention in Youth Courts
The proposed research is designed to adapt and test an evidence-based drug abuse prevention approach for use in youth courts among first-time, non-violent, adolescent offenders.
- Trial name
- NCT02764099
- Testing
- Life Skills Training
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Schizophrenia, Drug Abuse
A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse
The prevalence estimates for specific mental disorders and illicit drugs have been separately reported in U.S. government surveys.
- Conditions
- Schizophrenia, Drug Abuse, Anxiety Disorder, Bipolar Disorder
- Trial name
- NCT02476877
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Advanced Clinical Laboratory Solutions, Inc.
Pharmacokinetics, Tolerability
Clinical Trial on Pharmacokinetics and Tolerability of AP707
Brief Summary:This study aims to investigate the uptake of AP707, a preparation from cannabis flowers, into the bloodstream after in single administration in healthy volunteers.
- Conditions
- Pharmacokinetics, Tolerability, Safety
- Trial name
- NCT05267769
- Testing
- AP707
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CannaXan GmbH
Abuse, Drug
A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
The primary objective of this study was to evaluate the abuse potential of single doses of cebranopadol (GRT6005) relative to hydromorphone (immediate-release formulation [IR] and placebo in 48 non-dependent recreational opioid…
- Trial name
- NCT03757559
- Testing
- Cebranopadol 100 micrograms, Cebranopadol 400 micrograms, Hydromorphone hydrochloride 4 milligrams
- Where
- Canada
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Opioid-use Disorder
Improving Office Based Treatment of Opioid Use Disorder With Technology
The goal of this study is to evaluate whether using a novel drug-device combination to deliver buprenorphine/naloxone (B/N) to patients in office-based treatment for Opioid Use Disorder (OUD) is an effective way to improve…
- Trial name
- NCT03586466
- Testing
- BupreCare, Buprenorphine/naloxone, MEMS
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- MedicaSafe, Inc.
Opioid Related Disorders, Opiate Addiction
Monitoring Patterns of Prescribing to Identify Changes in Access to ER/LA Opioid Analgesics
Changes in prescribing will be compared in prescribers from specialties whose prescribing is hypothesized to be relatively unaffected by the REMS (such as oncologists and hospice providers) versus those for whom the REMS could…
- Conditions
- Opioid Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02920775
- Testing
- Non-interventional study - retrospective database review
- Volunteers
- 360,000 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
Drug Abuse
Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users
The primary objective of this study is to evaluate the abuse potential of intranasal esketamine (112 milligram and 84 mg) compared to racemic intravenous ketamine (0.5 mg/kg) in nondependent, recreational polydrug users of…
- Trial name
- NCT02682225
- Testing
- Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Narcolepsy
Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription
Patients will be followed up for max 18 months. Information on the Adverse Events and potential misuse or abuse of Xyrem ® will be collected.
- Trial name
- NCT00244465
- Where
- 41 sites in Austria, Belgium and 7 more
- Volunteers
- 750 people
- Sponsor
- UCB Pharma
Abuse, Drug
Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users
A double-blind, randomized crossover study to assess the subjective abuse potential of intravenous remimazolam compared to midazolam and placebo in recreational CNS depressant users
- Trial name
- NCT04110535
- Testing
- Remimazolam, Midazolam, Saline
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Paion UK Ltd.
Chronic Non-specific Low Back Pain
Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain
Analysis of the efficacy, maintenance of efficacy, long-term safety, and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in the treatment of patients with chronic…
- Trial name
- NCT04940741
- Testing
- VER-01
- Where
- Germany
- Volunteers
- 820 people
- Sponsor
- Vertanical GmbH
Smoking, Tobacco Use
Modern Nicotine Oral Product Abuse Liability
This is a two-site, open-label, randomized, 8-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine uptake…
- Trial name
- NCT06777784
- Testing
- Product A, Product B, Product C
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Opioid-related Disorders, Opioid Addiction
ER/LA Opioid Analgesics - Surveillance Monitoring of State Medical Examiner Databases
In April 2011, the U.S. Food and Drug Administration (FDA) determined that a class-wide risk evaluation and mitigation strategy (REMS) for all extended-release (ER) and long-acting (LA) opioid medications was necessary to support…
- Conditions
- Opioid-related Disorders, Opioid Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02897414
- Testing
- Surveillance of state medical examiner databases
- Volunteers
- 13,015 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
Prescription Drug Abuse (Not Dependent), Substance Use
Preventing Prescription Drug Abuse in Middle School Students
This project is designed to test a primary prevention approach to the problem of prescription drug misuse and abuse (PDA) among middle school students.
- Conditions
- Prescription Drug Abuse (Not Dependent), Substance Use, Substance Abuse
- Trial name
- MSPDA (NCT03129334)
- Testing
- LST Middle School Online
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- National Health Promotion Associates, Inc.
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused.
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Trial name
- NCT00248092
- Testing
- NRP104
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- New River Pharmaceuticals
Healthy, Cannabis
A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population
The objective of this study is to investigate the bioavailability of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) in an emulsion product against a comparator product.
- Trial name
- NCT04601207
- Testing
- Cannabis Preparation
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- New Age Ventures LLC
Alcohol Abuse, Drug Abuse
A Web App for Patients With Alcohol and Drug Use Problems in Primary Care
The objective of this pilot study is to evaluate the feasibility and technical merit of a web application for patients in primary care called Check-up and Choices (CC).
- Trial name
- NCT01830114
- Testing
- Web app
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Behavior Therapy Associates, LLP
Opioid-related Disorders, Opioid Addiction
ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning
Study to evaluate the impact of the ER/LA opioid REMS program on the incidence of Emergency Department visits and hospitalizations for overdose/poisoning and death among patients prescribed ER/LA opioid analgesics.
- Conditions
- Opioid-related Disorders, Opioid Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02866266
- Testing
- Retrospective database review
- Volunteers
- 183,452 people
- Sponsor
- ER/LA Opioid REMS Program Companies (RPC)
Recreational Drug Use
A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)
The purpose of this study is to examine the abuse potential and pharmacokinetics of PF614 compared with a non-abuse deterrent, commercially available, immediate release (IR) oxycodone hydrochloride (HCl) formulation and placebo.
- Trial name
- NCT05567354
- Testing
- PF614, Oxycodone
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Cannabis Abuse
Drug-Drug Interaction Between THC and AEF0117
This trial is a single center, double blind, placebo-controlled trial in healthy male and female recreational cannabis users with placebo and AEF0117 dosed in a fixed sequence.
- Trial name
- DDI (NCT06395688)
- Testing
- 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one
- Volunteers
- healthy volunteers welcome
- Sponsor
- Aelis Farma
Pain, Nausea
A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route
The purpose of this study is to assess the abuse potential of CL-108 tablets, including the abuse deterrent effects of promethazine, following oral administration, relative to hydrocodone/acetaminophen (APAP) tablets and placebo…
- Conditions
- Pain, Nausea, Vomiting
- Trial name
- NCT02712554
- Testing
- CL-108, M366
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Charleston Laboratories, Inc